• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

aTyr Pharma wins FDA fast track for muscular dystrophy therapy

October 24, 2016 By Sarah Faulkner

aTyr Pharma wins FDA Fast Track designation for muscular dystrophy therapyaTyr Pharma (NSDQ:LIFE) said today that its candidate Resolaris was granted fast track designation by the FDA for the treatment of facioscapulohumeral muscular dystrophy, making it the 1st therapeutic candidate to receive the designation for the rare form of muscular dystrophy.

Resolaris is derived from a naturally occurring protein released by human skeletal muscle cells. aTyr is exploring the use of Resolaris as a therapy for patients with rare myopathies with an immune component characterized by excessive immune cell involvement.

FSHD is a rare genetic myopathy that affects 19,000 people in the U.S., according to aTyr, and there are no approved treatments. Patients with FSHD suffer from skeletal muscle deterioration, fatigue, chronic pain and muscle weakness.

Resolaris is being studied in a Phase Ib/II clinical program as a treatment for FSHD, according to the San Diego-based company, and it expects to report data from 3 clinical trials in December.

The fast track designation is designed to expedite the review process for drug candidates that aim to treat rare and serious conditions. Product candidates may be eligible for priority review when the company submits a Biologic License Application. The company is also eligible for more frequent communication directly with the FDA.

“This fast track designation, which is granted to drug candidates addressing serious conditions and that demonstrate the potential to address unmet medical needs, represents another step forward for our rare muscle disease franchise,” CEO John Mendlein said in prepared remarks. “This designation highlights the significant need to develop and ultimately approve meaningful new therapeutics to treat patients with rare myopathies, such as FSHD.”

The company’s stock was trading at $3.05 apiece in late-afternoon trading activity, up 5.17%.

Filed Under: Clinical Trials, Featured, Food & Drug Administration (FDA), Regulatory/Compliance Tagged With: aTyr Pharma

IN CASE YOU MISSED IT

  • Omnipod 5 rollout for type 2 rolls on as Insulet pursues next-gen automation
  • LifePlus reports clinical validation of non-invasive glucose, blood pressure monitor
  • Abbott Diabetes head talks Medtronic partnership, exciting times ahead
  • PharmaSens, SiBionics innovatively combine tech in all-in-one insulin patch pump
  • Study backs Biolinq intradermal sensor in muscle loss prevention during GLP-1 therapy

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS